Back to top
more

CTI BioPharma Corp. (CTIC)

(Delayed Data from NSDQ)

$0.99 USD

0.99
130,400

+0.01 (1.49%)

Updated May 3, 2019 04:00 PM ET

After-Market: $0.99 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nektar (NKTR) delivered earnings and revenue surprises of 3.85% and 4.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

FibroGen (FGEN) delivered earnings and revenue surprises of -6.58% and 17.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will CTI BioPharma (CTIC) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

CTI BioPharma (CTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets

by Zacks Equity Research

The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.

CTI BioPharma (CTIC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -55.56% and 15.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Has CTI BioPharma (CTIC) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how CTI BioPharma (CTIC) and Esperion Therapeutics (ESPR) have performed compared to their sector so far this year.

CTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

CTI BioPharma (CTIC) delivered earnings and revenue surprises of 13.33% and 0.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5% and 20.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CTI BioPharma (CTIC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5.71% and 6.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CTI BioPharma (CTIC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -35.71% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy CTI BioPharma (CTIC) After Golden Cross?

by Zacks Equity Research

Is it a good or bad thing when a stock experiences a golden cross technical event?

The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma

Biotech Stock Roundup: VRTX, AMGN's Pipeline Updates, BPMC's Acquisition & More

by Zacks Equity Research

Pipeline updates from Vertex (VRTX) and Amgen (AMGN) and other acquisition and regulatory updates have been the biotech sector's few key highlights during the past week.

Implied Volatility Surging for CTI BioPharma (CTIC) Stock Options

by Zacks Equity Research

Investors need to pay close attention to CTI BioPharma (CTIC) stock based on the movements in the options market lately.

CTI BioPharma (CTIC) Dips on Top-Line Data from COVID-19 Study

by Zacks Equity Research

CTI BioPharma (CTIC) posts top-line data from the PRE-VENT study evaluating pacritinib/standard of care as a treatment of severe COVID-19 infection.

CTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -30.00% and 20.50%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in CTI BioPharma (CTIC) Stock?

by Zacks Equity Research

Investors need to pay close attention to CTI BioPharma (CTIC) stock based on the movements in the options market lately.

    CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    CTI BioPharma (CTIC) delivered earnings and revenue surprises of 13.04% and 104.33%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA

      by Zacks Equity Research

      CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.

        Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

        by Zacks Equity Research

        Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

          CTI BioPharma Falls After Failure of Pivotal Lymphoma Study

          by Zacks Equity Research

          CTI BioPharma (CTIC) and partner Servier announce that a pivotal study evaluating a Pixuvri combination regimen in non-Hodgkin lymphoma fails to improve progression free survival.